Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amneal Adds Another Complex Generic With TobraDex Approval

Expands Portfolio With Dexamethasone/Tobramycin Ophthalmic Suspension

Executive Summary

Amneal has broadened its complex generics portfolio by gaining FDA approval for its generic version of ophthalmic combination medicine TobraDex.

You may also be interested in...



Amneal Takes A Step Forward On Biosimilars

The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.

Amneal Targets Migraine With 505(b)(2) Filing

Amneal is setting its sights on the migraine and cluster headache market in the US with a new hybrid 505(b)(2) filing for a dihydroergotamine autoinjector.

Amneal Takes Control Of Kashiv Specialty In $100m+ Deal

Amneal will take a majority stake in Kashiv Specialty Pharmaceuticals after striking a deal worth potentially more than $100m for a 98% stake in the hybrid 505(b)(2) and complex generics specialist.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel